Menu Search
Equities

Capricor Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4LN2:FRA

Capricor Therapeutics Inc

Actions
  • Price (EUR)20.15
  • Today's Change-0.300 / -1.47%
  • Shares traded330.00
  • 1 Year change+54.52%
  • Beta0.4004
Data delayed at least 15 minutes, as of Feb 11 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

  • Revenue in USD (TTM)11.13m
  • Net income in USD-81.99m
  • Incorporated2007
  • Employees160.00
  • Location
    Capricor Therapeutics Inc10865 Road to the Cure, Suite 150SAN DIEGO 92121United StatesUSA
  • Phone+1 (310) 358-3200
  • Fax+1 (302) 655-5049
  • Websitehttps://capricor.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.